Detailed analysis of Brivaracetam instructions for use

Brivaracetam/Brivaracetam is a new anti-epileptic drug mainly used to treat partial epileptic seizures in patients aged 1 month and above. It acts as a high-affinity binder for synaptic vesicle protein2A (SV2A) and exerts anticonvulsant effects by regulating neuronal excitability. Compared with traditional anti-epileptic drugs, brivaracetam has a rapid onset of action, is well tolerated, and can be used in combination with a variety of anti-epileptic drugs, making it suitable for long-term management in adults and children.

1. Indications

Brivaracetam is indicated as a single agent or in combination for the treatment of partial seizures, especially in adults and children. It has a wide range of clinical applications and can improve patients' seizure frequency and help maintain daily living and learning abilities. Especially for patients who do not respond well to other anti-epileptic drugs, Brivaracetam provides a new treatment option.

2. Recommended dosage and usage

Brivaracetam tablets, oral solution, and injection may be used interchangeably. The usual initial oral dose for adults is 50 mg twice daily. The maintenance dose can be adjusted to 25 to 100 mg twice daily based on individual tolerance. The maximum dose is 200 mg/day. For patients who are temporarily unable to take oral medication, intravenous injection can be used, with the same dose as oral administration, 50 mg each time, injected over 2 to 15 minutes, twice a day, but the experience with intravenous medication is limited to 4 consecutive days. The dosage for children is strictly graded according to weight: the initial dosage for children less than 11 kg is 0.75 to 1.5 mg/kg, twice a day; the initial dosage for 11 to 20 kg is 0.5 to 1.25 mg/kg; the initial dosage for 20 to 50 kg is 0.5 to 1 mg/kg; for those 50 kg and above, refer to the adult dosage. Maintenance dose may be adjusted based on body weight and clinical response. If children aged 16 and above are temporarily unable to take oral medication, intravenous injection can also be used.

3. Adverse reactions

Mainly mild to moderate, common symptoms include drowsiness or sedation, dizziness, fatigue, nausea and vomiting. These reactions usually appear at the beginning of treatment and gradually resolve as the patient adapts to the drug. Compared with traditional antiepileptic drugs, brivaracetam has a lower side effect profile and is well tolerated, making it suitable for long-term maintenance treatment.

4. Pharmacological effects

The anticonvulsant mechanism of Brivaracetam and its effects on the brainRelevant to high-affinity binding of SV2A protein. SV2A protein plays a key role in neuronal vesicles and regulates neurotransmitter release. By selectively binding to SV2A, brivaracetam helps reduce abnormal neural discharges and stabilize neuronal activity, thereby effectively controlling epileptic seizures. Although its specific molecular mechanism has not been fully elucidated, clinical and experimental data have shown its significant efficacy in the management of partial seizures.

5. Storage conditions

Required to be stored at 25°C, allowed to fluctuate within the range of 15°C to 30°C. Injections and oral suspensions should never be frozen. Opened medicines must be used within 5 months, otherwise unused medicines should be discarded. Injection vials are for single use and avoid reuse to ensure drug safety.

In summary, brivaracetam is an anti-epileptic drug with innovative mechanism, significant efficacy and good tolerance. Its detailed instructions provide clear dosage references and medication specifications, allowing adult and pediatric patients to achieve safe and effective epilepsy management under the guidance of professional doctors. Through standardized dosage, continuous monitoring and symptomatic treatment, Brivaracetam is considered an important choice for the treatment of partial epilepsy in global clinical practice, providing patients with a precise, long-term and controllable treatment plan.

Reference materials:https://www.briviact.com/